The Next Leap in
Molecular Screening
The Next Leap
in Molecular Screening
REAL-TIME MOLECULAR DATA ON ONE CHIP
REAL-TIME MOLECULAR DATA ON ONE CHIP
A quantum-electrochemical device delivering ultra-sensitive drug discovery and screening across all molecule sizes, from small organics to complex biologics.
A quantum-electrochemical device delivering ultra-sensitive drug discovery and screening across all molecule sizes, from small organics to complex biologics.
REDEFINING DRUG DISCOVERY AT ITS CORE
REDEFINING DRUG DISCOVERY
AT ITS CORE
Qnity delivers faster, accessible molecular screening with quantum-level precision.
Qnity delivers faster, accessible molecular screening with quantum-level precision.
Qnity delivers faster, accessible molecular screening with quantum-level precision.
Peptide
Target Molecule "B"
Receptor Molecule "A"
Au Monolayer
Silicon Wafer
Chip
Peptide
Target Molecule "B"
Receptor Molecule "A"
Au Monolayer
Silicon Wafer
Chip
Explore the chip core
Peptide
Target Molecule "B"
Receptor Molecule "A"
Silicon Wafer
Au Monolayer
Chip
Inside the
Quantum Chip
Inside the
Quantum Chip
At the heart of Qnity is a custom chip built with nanogold-silicon electrodes and quantum sensing technology, designed to deliver:
At the heart of Qnity is a custom chip built with nanogold-silicon electrodes and quantum sensing technology, designed to deliver:
At the heart of Qnity is a custom chip built with nanogold-silicon electrodes and quantum sensing technology, designed to deliver:
Current State-of-the-Art
Future
Biophysical Parameters
High-sensitivity binding affinity screening at attomolar concentrations
Kinects Parameters
Real-time binding affinity analysis with high-throughput capability
Current State-of-the-Art
Future
Biophysical Parameters
High-sensitivity binding affinity screening at attomolar concentrations
Kinects Parameters
Real-time binding affinity analysis with high-throughput capability
Current State-of-the-Art
Biophysical Parameters
High-sensitivity binding affinity screening at attomolar concentrations
Future
Kinetic Parameters
Real-time binding affinity analysis with high-throughput capability
Applications in Drug Discovery
Built to accelerate discovery, Qnity enables precise, accessible screening in the most critical use cases.
Built to accelerate discovery, Qnity enables precise, accessible screening in the most critical use cases.
Macro Molecule Screening
Macro Molecule Screening
Small Molecule Screening
Small Molecule Screening
Macro Molecule Screening
Small Molecule Screening
Qnity. One chip. One platform.
Faster.
Faster.
Scalable.
More precise.
Qnity. One chip. One platform.
Faster.
Faster.
Scalable.
More precise.
Qnity. One chip.
One platform.
Faster.
Faster.
Scalable.
More precise.
Trusted by Innovators in Health and Quantum
Trusted by Innovators in Health and Quantum
Top organizations, pharmas, and industry leaders are already testing Qnity’s chip and seeing the future of molecular screening.
Top organizations, pharmas, and industry leaders are already testing Qnity’s chip and seeing the future of molecular screening.
"We selected Qnity to establish their U.S. headquarters in Tulsa because of their groundbreaking technology, global potential, and the exceptional drive of their founding team. Their vision is bold, and we’re confident they’ll achieve everything they set out to do. As part of our support, Qnity is receiving full soft-landing assistance, strategic investor access, potential customer connections, and non-dilutive funding."
— Marcos Bazzana, Managing Director,
Strategic Partnerships & Capital, LATAM to Tulsa - TLV"Qnity’s platform is truly revolutionary. They’re operating at the very limits of detection—measuring molecular interactions at concentrations that were previously unreachable. This isn’t just a leap forward, it’s a new era for drug discovery and diagnostics."
— Justin Briggs, Deep Tech VC
"We selected Qnity to establish their U.S. headquarters in Tulsa because of their groundbreaking technology, global potential, and the exceptional drive of their founding team. Their vision is bold, and we’re confident they’ll achieve everything they set out to do. As part of our support, Qnity is receiving full soft-landing assistance, strategic investor access, potential customer connections, and non-dilutive funding."
— Marcos Bazzana, Managing Director,
Strategic Partnerships & Capital, LATAM to Tulsa - TLV"Qnity’s platform is truly revolutionary. They’re operating at the very limits of detection—measuring molecular interactions at concentrations that were previously unreachable. This isn’t just a leap forward, it’s a new era for drug discovery and diagnostics."
— Justin Briggs, Deep Tech VC
"We selected Qnity to establish their U.S. headquarters in Tulsa because of their groundbreaking technology, global potential, and the exceptional drive of their founding team. Their vision is bold, and we’re confident they’ll achieve everything they set out to do. As part of our support, Qnity is receiving full soft-landing assistance, strategic investor access, potential customer connections, and non-dilutive funding."
— Marcos Bazzana, Managing Director,
Strategic Partnerships & Capital, LATAM to Tulsa - TLV"Qnity’s platform is truly revolutionary. They’re operating at the very limits of detection—measuring molecular interactions at concentrations that were previously unreachable. This isn’t just a leap forward, it’s a new era for drug discovery and diagnostics."
— Justin Briggs, Deep Tech VC
"We selected Qnity to establish their U.S. headquarters in Tulsa because of their groundbreaking technology, global potential, and the exceptional drive of their founding team. Their vision is bold, and we’re confident they’ll achieve everything they set out to do. As part of our support, Qnity is receiving full soft-landing assistance, strategic investor access, potential customer connections, and non-dilutive funding."
— Marcos Bazzana, Managing Director,
Strategic Partnerships & Capital, LATAM to Tulsa - TLV"Qnity’s platform is truly revolutionary. They’re operating at the very limits of detection—measuring molecular interactions at concentrations that were previously unreachable. This isn’t just a leap forward, it’s a new era for drug discovery and diagnostics."
— Justin Briggs, Deep Tech VC
"We selected Qnity to establish their U.S. headquarters in Tulsa because of their groundbreaking technology, global potential, and the exceptional drive of their founding team. Their vision is bold, and we’re confident they’ll achieve everything they set out to do. As part of our support, Qnity is receiving full soft-landing assistance, strategic investor access, potential customer connections, and non-dilutive funding."
— Marcos Bazzana, Managing Director,
Strategic Partnerships & Capital, LATAM to Tulsa - TLV"Qnity’s platform is truly revolutionary. They’re operating at the very limits of detection—measuring molecular interactions at concentrations that were previously unreachable. This isn’t just a leap forward, it’s a new era for drug discovery and diagnostics."
— Justin Briggs, Deep Tech VC
"We selected Qnity to establish their U.S. headquarters in Tulsa because of their groundbreaking technology, global potential, and the exceptional drive of their founding team. Their vision is bold, and we’re confident they’ll achieve everything they set out to do. As part of our support, Qnity is receiving full soft-landing assistance, strategic investor access, potential customer connections, and non-dilutive funding."
— Marcos Bazzana, Managing Director,
Strategic Partnerships & Capital, LATAM to Tulsa - TLV"Qnity’s platform is truly revolutionary. They’re operating at the very limits of detection—measuring molecular interactions at concentrations that were previously unreachable. This isn’t just a leap forward, it’s a new era for drug discovery and diagnostics."
— Justin Briggs, Deep Tech VC
"We selected Qnity to establish their U.S. headquarters in Tulsa because of their groundbreaking technology, global potential, and the exceptional drive of their founding team. Their vision is bold, and we’re confident they’ll achieve everything they set out to do. As part of our support, Qnity is receiving full soft-landing assistance, strategic investor access, potential customer connections, and non-dilutive funding."
— Marcos Bazzana, Managing Director,
Strategic Partnerships & Capital, LATAM to Tulsa - TLV"Qnity’s platform is truly revolutionary. They’re operating at the very limits of detection—measuring molecular interactions at concentrations that were previously unreachable. This isn’t just a leap forward, it’s a new era for drug discovery and diagnostics."
— Justin Briggs, Deep Tech VC
"We selected Qnity to establish their U.S. headquarters in Tulsa because of their groundbreaking technology, global potential, and the exceptional drive of their founding team. Their vision is bold, and we’re confident they’ll achieve everything they set out to do. As part of our support, Qnity is receiving full soft-landing assistance, strategic investor access, potential customer connections, and non-dilutive funding."
— Marcos Bazzana, Managing Director,
Strategic Partnerships & Capital, LATAM to Tulsa - TLV"Qnity’s platform is truly revolutionary. They’re operating at the very limits of detection—measuring molecular interactions at concentrations that were previously unreachable. This isn’t just a leap forward, it’s a new era for drug discovery and diagnostics."
— Justin Briggs, Deep Tech VC
"We selected Qnity to establish their U.S. headquarters in Tulsa because of their groundbreaking technology, global potential, and the exceptional drive of their founding team. Their vision is bold, and we’re confident they’ll achieve everything they set out to do. As part of our support, Qnity is receiving full soft-landing assistance, strategic investor access, potential customer connections, and non-dilutive funding."
— Marcos Bazzana, Managing Director, Strategic Partnerships & Capital, LATAM to Tulsa - TLV
"Qnity’s platform is truly revolutionary. They’re operating at the very limits of detection—measuring molecular interactions at concentrations that were previously unreachable. This isn’t just a leap forward, it’s a new era for drug discovery and diagnostics."
— Justin Briggs, Deep Tech VC
"We selected Qnity to establish their U.S. headquarters in Tulsa because of their groundbreaking technology, global potential, and the exceptional drive of their founding team. Their vision is bold, and we’re confident they’ll achieve everything they set out to do. As part of our support, Qnity is receiving full soft-landing assistance, strategic investor access, potential customer connections, and non-dilutive funding."
— Marcos Bazzana, Managing Director, Strategic Partnerships & Capital, LATAM to Tulsa - TLV
"Qnity’s platform is truly revolutionary. They’re operating at the very limits of detection—measuring molecular interactions at concentrations that were previously unreachable. This isn’t just a leap forward, it’s a new era for drug discovery and diagnostics."
— Justin Briggs, Deep Tech VC
"We selected Qnity to establish their U.S. headquarters in Tulsa because of their groundbreaking technology, global potential, and the exceptional drive of their founding team. Their vision is bold, and we’re confident they’ll achieve everything they set out to do. As part of our support, Qnity is receiving full soft-landing assistance, strategic investor access, potential customer connections, and non-dilutive funding."
— Marcos Bazzana, Managing Director, Strategic Partnerships & Capital, LATAM to Tulsa - TLV
"Qnity’s platform is truly revolutionary. They’re operating at the very limits of detection—measuring molecular interactions at concentrations that were previously unreachable. This isn’t just a leap forward, it’s a new era for drug discovery and diagnostics."
— Justin Briggs, Deep Tech VC
"We selected Qnity to establish their U.S. headquarters in Tulsa because of their groundbreaking technology, global potential, and the exceptional drive of their founding team. Their vision is bold, and we’re confident they’ll achieve everything they set out to do. As part of our support, Qnity is receiving full soft-landing assistance, strategic investor access, potential customer connections, and non-dilutive funding."
— Marcos Bazzana, Managing Director, Strategic Partnerships & Capital, LATAM to Tulsa - TLV
"Qnity’s platform is truly revolutionary. They’re operating at the very limits of detection—measuring molecular interactions at concentrations that were previously unreachable. This isn’t just a leap forward, it’s a new era for drug discovery and diagnostics."
— Justin Briggs, Deep Tech VC
Meet the Team
Meet the Team
Led by scientists, built for scientists.
Led by scientists, built for scientists.
Operational Team
Tech Advisory
Strategic Advisory
Operational Team
Tech Advisory
Strategic Advisory
Operational Team
Tech Advisory
Strategic Advisory
Join the Quantum Shift in Drug Discovery
Whether you're developing novel therapeutics, validating drug predictions, or building the next generation of precision diagnostics—we’d love to hear from you!
Join the Quantum Shift in Drug Discovery
Whether you're developing novel
therapeutics, validating drug predictions, or building the next generation of precision diagnostics
—we’d love to hear from you!
© 2025 Qnity | Powered by WeArePalta | All rights reserved.
© 2025 Qnity | Powered by WeArePalta | All rights reserved.
© 2025 Qnity | Powered by WeArePalta | All rights reserved.